Avandia :: Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature
A reanalysis of the data used in a previous analysis of the drug Rosiglitazone — marketed by GlaxoSmithKoine as Avandia — using different statistical models suggests that the earlier methodology may have resulted in inflated risk estimates.